Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: Rationale for targeting the β-adrenergic and renin-angiotensin systems

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 3, 2009, Pages

  Champetier, Serge ^a   Bojmehrani, Azadeh ^a   Beaudoin, Jonathan ^a   Lachance, Dominic ^a   Plante, Éric ^a   Roussel, Élise ^a   Couet, Jacques ^a,b   Arsenault, Marie ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Centre de Recherche Hôpital   (Canada)

Author keywords

Adrenergic system; Gene expression; Heart hypertrophy; Renin angiotensin system

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA; METOPROLOL; TRANSFORMING GROWTH FACTOR BETA2; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SCLEROPROTEIN;

ACUTE DISEASE; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE REGURGITATION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HEART LEFT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; DISEASE MODEL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; HEART VENTRICLE; HOSPITALIZATION; METABOLISM; METHODOLOGY; TIME; WISTAR RAT;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTIC VALVE INSUFFICIENCY; CAPTOPRIL; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; MALE; METOPROLOL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 64049117047     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01046.2008     Document Type: Article

References (44)

1. Ackermann GE, Marenholz I, Wolfer DP, Chan WY, Schafer B, Erne P, Heizmann CW. S100A1-deficient male mice exhibit increased exploratory activity and reduced anxiety-related responses. Biochim Biophys Acta 1763: 1307-1319, 2006.
2. Arsenault M, Plante E, Drolet MC, Couet J. Experimental aortic regurgitation in rats under echocardiographic guidance. J Heart Valve Dis 11: 128-134, 2002.
3. Bitar FF, Hayek P, Obeid M, Gharzeddine W, Mikati M, Dbaibo GS. Rheumatic fever in children: a 15-year experience in a developing country. Pediatr Cardiol 21: 119-122, 2000.
4. Bonow RO. Aortic regurgitation. Curr Treat Options Cardiovasc Med 2: 125-132, 2000.
5. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114: e84-e231, 2006.
6. Borer JS, Herrold EM, Hochreiter CA, Supino PG, Yin A, Krieger KH, Isom OW. Aortic regurgitation: selection of asymptomatic patients for valve surgery. Adv Cardiol 39: 74 -85, 2002.
7. Borer JS, Truter SL, Gupta A, Herrold EM, Carter JN, Lee E, Pitlor L. Heart failure in aortic regurgitation: the role of primary fibrosis and its cellular and molecular pathophysiology. Adv Cardiol 41: 16 -24, 2004.
8. Braun MU, LaRosee P, Simonis G, Borst MM, Strasser RH. Regulation of protein kinase C isozymes in volume overload cardiac hypertrophy. Mol Cell Biochem 262: 135-143, 2004.
9. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail 11: 548-556, 2005.
10. Chandrashekhar Y. Embracing diversity in remodeling: a step in therapeutic decision making in heart failure? J Am Coll Cardiol 49: 822-825, 2007.
11. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 32: 1805819, 2000.
12. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 32: 1805819, 2000.
13. Chockalingam A, Gnanavelu G, Elangovan S, Chockalingam V. Current profile of acute rheumatic fever and valvulitis in southern India. J Heart Valve Dis 12: 573-576, 2003.
14. Couet J, Gaudreau M, Lachance D, Plante E, Roussel E, Drolet MC, Arsenault M. Treatment of combined aortic regurgitation and systemic hypertension: insights from an animal model study. Am J Hypertens 19:843-850, 2006.
15. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 353: 1342349, 2005.
16. Frank D, Kuhn C, Brors B, Hanselmann C, Ludde M, Katus HA, Frey N. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension 51: 309-318, 2008.
17. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 370: 274-278, 2008.
18. Kiewitz R, Acklin C, Minder E, Huber PR, Schafer BW, Heizmann CW. S100A1, a new marker for acute myocardial ischemia. Biochem Biophys Res Commun 274: 865-871, 2000.
19. Lachance D, Plante E, Roussel E, Drolet MC, Couet J, Arsenault M. Early left ventricular remodeling in acute severe aortic regurgitation: insights from an animal model. J Heart Valve Dis 17: 300-308, 2008.
20. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M, Lee ET, Fabsitz RR, Welty TK, Howard BV, Devereux RB. Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. J Am Coll Cardiol 36: 461-467, 2000.
21. Leon LR Jr, Arslan B, Ley E, Labropoulos N. Endovascular therapy of spontaneous aortocaval fistulae associated with abdominal aortic aneu- rysms. Vascular 15: 35-40, 2007.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 25: 402-408, 2001.
23. Maron BJ, Ferrans VJ, Roberts WC. Myocardial ultrastructure in patients with chronic aortic valve disease. Am J Cardiol 35: 725-739, 1975.
24. Matsui Y, Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol 37: 477-481, 2004.
25. Miyazaki H, Oka N, Koga A, Ohmura H, Ueda T, Imaizumi T. Comparison of gene expression profiling in pressure and volume overload- induced myocardial hypertrophies in rats. Hypertens Res 29: 1029 045, 2006.
26. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M, Niroomand F, Pieske B, Janssen PM, Eschenhagen T, Karczewski P, Smith GL, Koch WJ, Katus HA, Remppis A. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 98: 138893894, 2001.
27. Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D, Loffler E, Janssen PM, Eckhart AD, Martini J, Williams ML, Katus HA, Remppis A, Koch WJ. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 114: 1550 563, 2004.
28. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 293: R568 -R577, 2007.
29. Plante E, Couet J, Gaudreau M, Dumas MP, Drolet MC, Arsenault M. Left ventricular response to sustained volume overload from chronic aortic valve regurgitation in rats. J Card Fail 9: 128 40, 2003.
30. Plante E, Gaudreau M, Lachance D, Drolet MC, Roussel E, Gauthier C, Lapointe E, Arsenault M, Couet J. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Can J Physiol Pharmacol 82:19199, 2004.
31. Plante E, Lachance D, Champetier S, Drolet MC, Roussel E, Arsenault M, Couet J. Benefits of long-term β-blockade in experimental chronic aortic regurgitation. Am J Physiol Heart Circ Physiol 294: H1888-H1895, 2008.
32. Plante E, Lachance D, Gaudreau M, Drolet MC, Roussel E, Arsenault M, Couet J. Effectiveness of beta-blockade in experimental chronic aortic regurgitation. Circulation 110: 1477483, 2004.
33. Plante E, Lachance D, Roussel E, Drolet MC, Arsenault M, Couet J. Impact of anesthesia on echocardiographic evaluation of systolic and diastolic function in rats. J Am Soc Echocardiogr 19: 1520 525, 2006.
34. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98: 3328-3333, 2001.
35. Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci USA 103:7327-7332, 2006.
36. Schaffer WL, Galloway JM, Roman MJ, Palmieri V, Liu JE, Lee ET, Best LG, Fabsitz RR, Howard BV, Devereux RB. Prevalence and correlates of rheumatic heart disease in American Indians (the Strong Heart Study). Am J Cardiol 91: 1379382, 2003.
37. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R, Komuro I. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100: 2449-2454, 1999.
38. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87: 1663667, 1990.
39. van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res 94:e18 -e26, 2004.
40. Wagner RA, Tabibiazar R, Powers J, Bernstein D, Quertermous T. Genome-wide expression profiling of a cardiac pressure overload model identifies major metabolic and signaling pathway responses. J Mol Cell Cardiol 37: 1159170, 2004.
41. Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, Dai M, John SW, Chen YF. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 42: 88 -95, 2003.
42. Weinberg EO, Mirotsou M, Gannon J, Dzau VJ, Lee RT, Pratt RE. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 12: 11327, 2003.
43. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-2455, 2003.
44. Yang DK, Choi BY, Lee YH, Kim YG, Cho MC, Hong SE, Kim dH, Hajjar RJ, Park WJ. Gene profiling during regression of pressure overload-induced cardiac hypertrophy. Physiol Genomics 30: 1-7, 2007.